-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

Benzinga·09/15/2026 13:52:09
Listen to the news
Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.